powered by Ambry Genetics®
RNA genetic testing addresses some of the limitations associated with DNA testing alone.
Use of +RNAinsight® in tandem with DNA testing provides additional data to refine variant classification as well as resolve Variants of Unknown Significance (VUS).
Expanded RNA Analysis enables better variant classification and also identifies deep-intronic mutations which can go undetected in DNA-only testing.
breast, colorectal, ovarian, uterine, pancreatic, prostate, melanoma, stomach + other cancers
Whole Blood (DNA) EDTA tube
Whole Blood (RNA) PAXgene tube
14-21 days from receipt of specimen
Up to 91 genes; expanded RNA analysis for better variant classification
Simultaneous RNA and DNA genetic testing for more accurate, actionable results
Decreases splicing variants of unknown significance (VUS) in real time
Increase in diagnostic yield
Sequence enrichment of targeted coding exons and adjacent intronic regions by PCR and NGS